Nanogenics owns and develops virus-like lipid nanoparticles for the delivery of nucleic acids and drugs to specific tissues such as tumours, lung epithelium, and CNS. We license our technology to biotech and big pharma companies in need of effective delivery to specific tissues. In this way we co-develop a range of gene therapies targeting cancer, cystic fibrosis, and eye diseases....
Nanogenics owns and develops virus-like lipid nanoparticles for the delivery of nucleic acids and drugs to specific tissues such as tumours, lung epithelium, and CNS. We license our technology to biotech and big pharma companies in need of effective delivery to specific tissues. In this way we co-develop a range of gene therapies targeting cancer, cystic fibrosis, and eye diseases.
More information

Employees

Jonathan Lane
Admin
Jonathan Lane Business Development Director Business Development